HOME >> BIOLOGY >> NEWS
In harshest environments, some proteins protected by 'alternate' folding mode

Beset by peers trying to tear them apart, proteins known as proteases constantly risk destruction. UCSF scientists have determined how a nearly impregnable design protects some of the most besieged proteases, a design that contradicts a basic assumption of chemistry.

The UCSF team studied alpha-lytic protease, a protein that breaks down nutrients for bacteria in the soil, an unforgiving environment where hundreds of protease species slash at each other. They found that the alpha-lytic protease is about 100 times more resistant to attack by other proteases than are digestive enzymes or other conventional proteases.

The key to this toughness, the scientists discovered, is the novel way the protease is folded into working order, a process fundamentally different from the effortless way most proteins fold into action and one that requires more energy at the outset but achieves remarkable stability.

They suspect this design strategy is mimicked in other environments extremely vulnerable to protease destruction, including lysosomes in human cells, where proteins are broken down for recycling.

The UCSF research is published in the January 17 issue of the journal Nature.

Most proteins -- made of linear chains of amino acids fold spontaneously into their working configuration, a shape that represents their most relaxed condition -- their lowest energy state. They occasionally unfold to some degree and then refold -- "breathing" as chemists call it. Whenever they do unfold, proteins risk attack by proteases designed to tear at newly exposed regions.

But the alpha-lytic protease does not spontaneously fold into a ready-to-work shape. It must be bent into working condition by a catalyst that temporarily becomes part of the molecule and is known as the pro-region. The UCSF researchers found that the structure sculpted by the pro-region is remarkably resistant to unfolding. Whereas normal proteins transiently unf
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
16-Jan-2002


Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New dye directly reveals activated proteins in living cells
3. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
4. Scientists discover proteins involved in spread of HIV-1 infection
5. New mechanism for display of foreign proteins to immune system
6. Scientists visualise cellular handmaiden that restores shape to proteins
7. Hopkins scientists use blood proteins to detect ovarian cancer
8. Viral proteins may prevent bacterial infections
9. Misfiring proteins tied to inflammation and sick feeling of type 2 diabetics
10. Good bacteria trigger proteins to protect the gut
11. Harmless virus helps slow HIV by boosting immune proteins

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the ... into their drug discovery research workflows with biology ranging from single cell-type spheroids ... of in vitro studies, they create several challenges that need to be overcome ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human Factors and product ... a new usability/observation room. This addition will help meet the increased industry demand ... delivery devices/combination products are safe and easy to use when released to the ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... Fla. (PRWEB) , ... January ... ... Geometrical Implant Co, (SAGICO), an innovative spinal implant company, announced today that ... in San Francisco, California. The annual J.P. Morgan Healthcare Conference is ...
(Date:1/7/2019)... SEONGNAM, South Korea (PRWEB) , ... January 07, ... ... has completed Phase 1 clinical trials of its Parkinson's Disease drug candidate, code-named ... disease-modifying treatment of Parkinson's Disease. The trial took place in South Korea. ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
Breaking Biology Technology:
Cached News: